G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.4 GBX -2.04% Market Closed
Market Cap: 13m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genedrive PLC
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Common Shares Outstanding
ÂŁ153m
CAGR 3-Years
34%
CAGR 5-Years
35%
CAGR 10-Years
32%
Oxford Nanopore Technologies PLC
LSE:ONT
Common Shares Outstanding
ÂŁ859.2m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Common Shares Outstanding
ÂŁ84.5m
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Common Shares Outstanding
ÂŁ50.8m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Common Shares Outstanding
ÂŁ252.2m
CAGR 3-Years
4%
CAGR 5-Years
34%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Common Shares Outstanding
ÂŁ680.4m
CAGR 3-Years
0%
CAGR 5-Years
22%
CAGR 10-Years
38%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
13m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.41 GBX
Overvaluation 83%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Common Shares Outstanding?
Common Shares Outstanding
153m GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Common Shares Outstanding amounts to 153m GBP.

What is Genedrive PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
32%

Over the last year, the Common Shares Outstanding growth was 32%. The average annual Common Shares Outstanding growth rates for Genedrive PLC have been 34% over the past three years , 35% over the past five years , and 32% over the past ten years .

Back to Top